Caricamento...
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
INTRODUCTION: Targeted therapy for NSCLC is rapidly evolving. EGFR-TKIs benefit NSCLC patients with sensitive EGFR mutations and significantly prolong survival. However, 20–30% of patients demonstrate primary resistance to EGFR-TKIs, which leads to the failure of EGFR-TKI treatment. The mechanisms o...
Salvato in:
| Pubblicato in: | Mol Med |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7329552/ https://ncbi.nlm.nih.gov/pubmed/32611363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00193-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|